Hoth Therapeutics Announces Extension of Washington University Alzheimer’s Mouse Model Study with Alzheimer’s Therapeutic HT-ALZ

June 13, 2022

The focus of the new studies is to determine a human equivalent dose of HT-ALZ for starting human clinical trials
NEW YORK Hoth Therapeutics, Inc. (NASDAQ: HOTH ), a patient-focused biopharmaceutical company, today announced that it has entered into an extension of its Sponsored Research Agreement with Washington University in St. Louis to support the continued research and development of HT-ALZ , a novel therapeutic for the treatment of Alzheimer’s disease .

Read the source article at PR Newswire
2022-06-09 12:18:00

Share This Story!